Back to search

Peptide record

TPDB10063

Antibacterial Hemolysis Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10063
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
WFGKLYRGITSVVKKVKGLLSG
Physicochemical Analysis
C116H190N30O27
ANDCEQHMP
GK
2436.97
11.04
5
0
10
+5
-0.49
0.232
110.45
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
6990
286.83
4
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
1
I
3
L
4
K
0
M
1
F
0
P
2
S
1
T
1
W
1
Y
3
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 3 K: 4 M: 0 F: 1 P: 0 S: 2 T: 1 W: 1 Y: 1 V: 3
Chemical Descriptors
22
C116H190N30O27
2436.97
11.04
+5
-0.49
0.232
Evidence Records 12 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.6-2.6 µM

Target

Klebsiella pneumoniae KPC

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.6-2.6 uM), ESBL E. coli (MIC 1.3-2.6 uM), XDR A. baumannii (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC
Evidence 2 Activity

Activity

MIC
Antibacterial
1.3-2.6 µM

Target

Escherichia coli

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.6-2.6 uM), ESBL E. coli (MIC 1.3-2.6 uM), XDR A. baumannii (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC 1.3-5.1 uM), S. aureus MRSA (M
Evidence 3 Activity

Activity

MIC
Antibacterial
0.6-2.6 µM

Target

A. baumannii

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.6-2.6 uM), ESBL E. coli (MIC 1.3-2.6 uM), XDR A. baumannii (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC 1.3-5.1 uM), S. aureus MRSA (MIC 5.1-20.5 uM), S. epidermidis (MI
Evidence 4 Activity

Activity

MIC
Antibacterial
1.3-5.1 µM

Target

Pseudomonas aeruginosa

Source & Reference

NA

Other

C (MIC 0.6-2.6 uM), ESBL E. coli (MIC 1.3-2.6 uM), XDR A. baumannii (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC 1.3-5.1 uM), S. aureus MRSA (MIC 5.1-20.5 uM), S. epidermidis (MIC 1.3-5.1 uM), and E. faecalis anti-
Evidence 5 Activity

Activity

MIC
Antibacterial
5.1-20.5 µM

Target

Staphylococcus aureus MRSA

Source & Reference

NA

Other

(MIC 1.3-2.6 uM), XDR A. baumannii (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC 1.3-5.1 uM), S. aureus MRSA (MIC 5.1-20.5 uM), S. epidermidis (MIC 1.3-5.1 uM), and E. faecalis anti-VRE (MIC 1.3-5.1 uM). In total, 70
Evidence 6 Activity

Activity

MIC
Antibacterial
1.3-5.1 µM

Target

Staphylococcus epidermidis

Source & Reference

NA

Other

i (MIC 0.6-2.6 uM), MDR P. aeruginosa (MIC 1.3-5.1 uM), S. aureus MRSA (MIC 5.1-20.5 uM), S. epidermidis (MIC 1.3-5.1 uM), and E. faecalis anti-VRE (MIC 1.3-5.1 uM). In total, 70 clinical strains were tested and
Evidence 7 Activity

Activity

MIC
Antibacterial
1.3-5.1 µM

Target

Enterococcus faecalis anti-VRE

Source & Reference

NA

Other

(MIC 1.3-5.1 uM), S. aureus MRSA (MIC 5.1-20.5 uM), S. epidermidis (MIC 1.3-5.1 uM), and E. faecalis anti-VRE (MIC 1.3-5.1 uM). In total, 70 clinical strains were tested and the results are expressed as a range.
Evidence 8 Activity

Activity

10% Hemolysis
Toxicity
9 µM
Hemolytic Cytotoxic
10% Hemolysis | 9 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 9 Activity

Activity

35% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
35% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 10 Activity

Activity

60% Killing
Toxicity
6.3 µM
Cytotoxic
60% Killing | 6.3 | µM | target cell: Human fibroblasts FB789

Target

Human fibroblasts FB789

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 11 Activity

Activity

100% Killing
Toxicity
12.5 µM
Cytotoxic
100% Killing | 12.5 | µM | target cell: Human fibroblasts FB789

Target

Human fibroblasts FB789

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 12 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis